Effects of anticancer drugs on transcription factor-DNA interactions

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 3, 2005, Pages 471-489

  Gniazdowski, Marek ^a   Denny, William A ^b   Nelson, Stephanie M ^b   Czyz, Malgorzata ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Anticancer drug; DNA antigene; Intercalation; Minor groove; Oligonucleotide; Peptide nucleic acid; Polyamide; Transcription factor

Indexed keywords

2' O 4' C METHYLENE BETA DEXTRO RIBOFURANOSYLNUCLEOTIDE; 4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; 4 FORMYL 6,9 DIHYDROXY 14 OXA 1,11 DIAZATETRACYCLO[7.4.1.0 2,7 0 10,12]TETRADECA 2,4,6 TRIEN 8 YLMETHYLCARBAMATE; 4',6 DIAMIDINO 2 PHENYLINDOLE; ACRIDINE DERIVATIVE; ACRIDINECARBOXAMIDE DERIVITIVE; ALKYLATING AGENT; AMINOACRIDINE; AMSACRINE; ANTHRACYCLINE DERIVATIVE; ANTHRAMYCIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BBR 3464; BENZIMIDAZOLE DERIVATIVE; BINDING PROTEIN; BRACO 19; CHLORAMBUCIL; CHLORMETHINE; CHROMOMYCIN A3; CISPLATIN; CONGOCIDINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DACTINOMYCIN; DAUNORUBICIN; DISTAMYCIN A; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ECHINOMYCIN; ETHIDIUM BROMIDE; GYRASE INHIBITOR; HEDAMYCIN; HOE 33342; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCALATING AGENT; LOCKED NUCLEIC ACID; MELPHALAN; MEPACRINE; MITHRAMYCIN; MITOMYCIN C; MITOXANTRONE; NOGALAMYCIN; NUTLIN 1; PEPTIDE NUCLEIC ACID; PLURAMYCIN; POLYAMIDE; RACHELMYCIN; REGULATOR PROTEIN; RETINOIC ACID; TALLIMUSTINE; TATA BINDING PROTEIN; TELOMERASE; THALIDOMIDE; TILORONE; TRABECTEDIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F4; TRANSPLATIN; TRIOSTIN C; UNCLASSIFIED DRUG; VASCULOTROPIN; WP 631;

DNA ALKYLATION; DNA MODIFICATION; DNA SEQUENCE; DNA STRUCTURE; DRUG BINDING SITE; DRUG DESIGN; DRUG DNA INTERACTION; DRUG EFFICACY; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; NONHUMAN; PROTEIN DNA BINDING; PROTEIN DNA INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; DNA; HUMANS; NEOPLASMS; PROTEIN BINDING; TRANSCRIPTION FACTORS;

EID: 21244481362     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.3.471     Document Type: Review

References (123)

1. KOHN KW, JACKMAN J, O'CONNOR PM: Cell cycle control and cancer chemotherapy. J. Cell. Biochem. (1994) 54:440-452.
2. HURST HC: Transcription factors as drug targets in cancer. Eur. J. Cancer (1996) 32A:1857-1863.
3. HURLEY LH: DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer (2002) 2:188-200.
4. WOYNAROWSKI JM: Targeting critical regions in genomic DNA with AT-specific anticancer drugs. Biochim. Biophys. Acta (2002) 1587:300-308.
5. KARAMOUZIS MV, GORGOULIS VG, PAPAVASSILIOU AG: Transcription factors and neoplasia: Vistas in novel drug design. Clin. Cancer Res. (2002) 8:949-961.
6. BERARDI P, RUSSELL M, EL-OSTA A, RIABOWOL K: Functional links between transcription, DNA repair and apoptosis. Cell. Mol. Life Sci. (2004) 61:2173-2180.
7. BROXTERMAN HJ, GEORGOPAPADAKOU NH: New cancer therapeutics: target-specific in, cytotoxics out? Drug Resist. Update (2004) 7:79-87.
8. ADAMS J: The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer (2004) 4:349-360.
9. GNIAZDOWSKI M, CZYZ M: Transcription factors as targets of anticancer drugs. Acta Biochim. Pol. (1999) 46:255-262.
10. GNIAZDOWSKI M, DENNY WA, NELSON SM, CZYZ M: Transcription factors as targets for DNA-interacting drugs. Curr. Med. Chem. (2003) 10:909H924.
11. ZEWAIL-FOOTE M, HURLEY LH: Molecular approaches to achieving control of gene expression by drug intervention at the transcriptional level. Anticancer Drug Des. (1999) 14:1-9.
12. VENTER JC, ADAMS MD, MYERS EW et al.: The sequence of the human genome. Science (2001) 291:1304-1351.
13. ORPHANIDES G, LAGRANGE T, REINBERG D: The general transcription factors of RNA polymerase II. Gene Develop. (1996) 10:2657-2683.
14. PATIGLOU G, BURLEY SK: Eukaryotic transcription factor-DNA complexes. Ann. Rev. Biophys. Biomol. Struct. (1997) 26:289H325.
15. GOLDBERG IH, REICH E, RABINOWITZ M: Inhibition of RNA polymerase reactions by actinomycin and proflavine. Nature (1963) 199:44-46.
16. GALE EF, CUNDLIFFE E, REYNOLDS PE, RICHMOND MH, WARING MJ: Inhibitors of nucleic acid synthesis. In: The Molecular Basis of Antibiotic Action (1981) pp. 258-401, WILEY NY.
17. BAGULEY BC: DNA intercalating antiHtumour agents. Anticancer Drug Des. (1991) 6:1-35.
18. BRANA MF, CACHO M, GRADILLAS A, DE PASCUAL-TERESA B, RAMOS A: Intercalators as anticancer drugs. Curr. Pharmaceut. Design (2001) 7:1745-1780.
19. GNIAZDOWSKI M, CERA C: The effects of DNA covalent adducts on in vitro transcription. Chem. Rev. (1996) 96:619-634.
20. WELCH JJ, RAUSCHER III FJ, BEERMAN TA: Targeting DNA-binding drugs to sequence-specific transcription factor-DNA complexes. J. Biol. Chem. (1994) 269:31051-31058.
21. BELLORINI M, MONCOLLIN V, D'INCALCI M, MONGELLI N, MANTOVANI R: Distamycin A and tallimustine inhibit TBP binding and basal in vitro transcription. Nucleic Acids Res. (1995) 23:1657-1663.
22. BRUICE TC, SENGUPTA D, BLASKO A, CHIANG S-Y, BEERMAN TA: A microgonotropen branched decaaza decabutylamine and its DNA and DNA/transcription factor interactions. Bioorg. Med. Chem. (1997) 5:685-692.
23. BONFANTI M, LA VALLE E, FARO J-MFS et al.: Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des. (1999) 14:179H186.
24. SUN D, HURLEY LH: TBP binding to the TATA box induces a specific downstream unwinding site that is targeted by pluramycin. Chem. Biol. (1995) 2:457H469.
25. VICHI P, COIN F, RENAUD J-P et al.: Cisplatin- and UV-damaged DNA lure the basal transcription Factor IID/TBP. EMBO J. (1997) 16:7444-7456.
26. JUNG Y, MIKATA Y, LIPPARD SJ: Kinetic studies of the TATA-binding protein interaction with cisplatin-modified DNA. J. Biol. Chem. (2001) 276:43589H43596.
27. WEI M, COHEN SM, SILVERMAN AP, LIPPARD SJ: Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins. J. Biol. Chem. (2001) 276:38774-38780.
28. CZYZ M, GNIAZDOWSKI M: Actinomycin D specifically inhibits the interaction between transcription factor Sp1 and its binding site. Acta Biochim. Pol. (1998) 45:67-73.
29. BIANCHI N, PASSADORE M, RUTIGLIANO C, FERIOTTO G, MISCHIATI C, GAMBARI R: Targeting of the Sp1 binding sites of HIV-1 long terminal repeat with chromomycin. Biochem. Pharmacol. (1996) 52:1489-1498.
30. CHIANG S-Y, AZIZKHAN JC, BEERMAN TA: A comparison of DNA-binding drugs as inhibitors of E2F1 and Sp1-DNA complexes and associated gene expression. Biochemistry (1998) 37:3109-3115.
31. PORTUGAL J, MARTIN B, VAQUERO A, FERRER N, VILLAMARIN S, PRIEBE W: Analysis of the effects of daunorubicin and WP 631 on transcription. Curr. Med. Chem. (2001) 8:1-8.
32. SZULAWSKA A, GNIAZDOWSKI M, CZYZ M: Sequence specificity of formaldehyde-mediated covalent binding of anthacycline derivatives to DNA. Biochem. Pharmacol. (2005) 69:7-18.
33. SUN D, HURLEY LH: Binding of Sp1 to the 21-bp repeat region of SV40 DNA: effect of intrinsic and drug-induced DNA bending between GC boxes. Gene (1994) 149:165-172.
34. MACLEOD MC, POWELL KL, KUZMIN VA, KOLBANOVSKIY A, GEACINTOV NE: Interference of benzo[a]pyrene diol epoxide-deoxyguanosine adducts in a GC box with binding of the transcription factor Sp1. Mol. Carcinogen. (1996) 16:44-52.
35. BROGGINI M, D'INCALCI M: Modulation of transcription factor-DNA interactions by anticancer drugs. Anticancer Drug Des. (1994) 9:373-387.
36. TAYLOR A, WEBSTER KA, GUSTAFSON TA, KEDES L: The anti-cancer agent distamycin A displaces essential transcription factors and selectively inhibits myogenic differentiation. Mol. Cell. Biochem. (1997) 169:61-72.
37. HO SN, BOYER SH, SCHREIBER SL, DANISHEFSKY SJ, CRABTREE GR: Specific inhibition of formation of transcription complexes by a calicheamicin oligosaccharide: A paradigm for the development of transcriptional antagonists. Proc. Natl. Acad. Sci. USA (1994) 91:9203H9207.
38. MACLEOD MC, POWELL KL, TRAN N: Binding of the transcription factor, Sp1, to non-target sites in DNA modified by benzo[a]pyrene diol epoxide. Carcinogenesis (1995) 16:975-983.
39. STUHLMEIER KM: Effects of quinacrine on endothelial cell morphology and transcription factor-DNA interactions. Biochim. Biophys. Acta (2000) 1524:57-65.
40. CHIANG S-Y, BRUICE TC, AZIZKHAN JC, GAWRON L, BEERMAN TA: Targeting E2F1-DNA complex with microgonotropen DNA binding agents. Proc. Natl. Acad. Sci. USA (1997) 94:2811-2816.
41. JOHNSON DG, COLEMAN A, POWELL KL, MACLEOD MC: High-affinity binding of the cell cycleHregulated transcription factors E2F1 and E2f4 to benzo[a]pyrene diol epoxide-DNA adducts. Mol. Carcinogen. (1997) 20:216-223.
42. DICKINSON LE, TRAUG ER JW, BAIRD EE, DERVAN PB, GRAVES BJ, GOTTESFELD JM: Inhibition of Ets-1 DNA binding and ternary complex formation between Ets-1, NF-κB, and DNA by a designed DNA-binding ligand. J. Biol. Chem. (1999) 274:12765-12773.
43. CHIANG SY, BURLI RW, BENZ CC et al.: Targeting the Ets binding site of the HER2/neu promoter with pyrrole-imidazole polyamides. J. Biol. Chem. (2000) 275:24246-24254.
44. WURTZ NR, POMERANTZ JL, BALTIMORE D, DERVAN PB: Inhibition of DNA binding by NF-kappa B with pyrrole-imidazole polyamides. Biochemistry (2002) 41:7604H7609.
45. TURNER PR, DENNY WA: The genome as a drug target: Sequence specific minor groove binding ligands. Curr. Drug Targets (2000) 1:1-14.
46. WHITE CM, HEIDENREICH O, NORDHEIM A, BEERMAN TA: Evaluation of the effectiveness of DNA-binding drugs to inhibit transcription using the c-fos serum response element as a target. Biochemistry (2000) 39:12262-12273.
47. WANG YD, DZIEGIELEWSKI J, WURTZ NR, DZIEGIELEWSKA B, DERVAN PB, BEERMAN TA: DNA crosslinking and biological activity of a hairpin polyamide chlorambucil conjugate. Nucleic Acids Res. (2003) 31:1208-1215.
48. GIESEG MA, DE BOCK C, TURNER PM, FERGUSON LR, DENNY WA: The effect of DNA-alkylating agents on gene expression from two integrated reporter genes in the cell line EMT6. Anticancer Drugs (2002) 13:271-280.
49. DENNY WA, BAGULEY BC: Dual topoisomerase I/II inhibitors in cancer therapy. Curr. Top. Med. Chem. (2003) 3:339-353.
50. VAN DYKE MW, DERVAN PB: Methidiumpropyl-EDTA.Fe(II) and DNase I footprinting report different small molecule binding site sizes on DNA. Nucleic Acids Res. (1983) 11:5555-5567.
51. WAKELIN LPG, ATWELL GJ, REWCASTLE GW, DENNY WA: Relationships between DNA-binding kinetics and biological activity for the 9Haminoacridine-4-carboxamide class of antitumor agents. J. Med. Chem. (1987) 30:855-861.
52. WHITE RJ, PHILLIPS DR: SequenceHdependent termination of bacteriophage T7 transcription in vitro by DNA-binding drugs. Biochemistry (1989) 28:4277-4283.
53. LENG F, CHAIRES JB, WARING MJ: Energetics of echinomycin binding to DNA. Nucleic Acids Res. (2003) 31:6191H6197.
54. FOX KR, WEBSTER R, PHELPS RJ, FOKT I, PRIEBE W: Sequence selective binding of bis-daunorubicin WP631 to DNA Eur. J. Biochem. (2004) 271:3556H3566.
55. CHAIRES JB, PRIEBE W, GRAVES DE, BURKE TG: Dissection of the free energy of anthracycline antibiotic binding to DNA: Electrostatic contributions. J. Am. Chem. Soc. (1993) 115:5360-5364.
56. BAILLY C: Topoisomerase I poisons and suppressors as anticancer drugs. Curr. Med. Chem. (2000) 7:39-58.
57. CHAKRABARTI S, BHATTACHARYYA D, DASGUPTA D: Structural basis of DNA recognition by anticancer antibiotics, chromomycin A3, and mithramycin: roles of minor groove width and ligand flexibility. Biopolymers (2001) 56:85-95.
58. KOPKA ML, GOODSELL DS, HAN GW, CHIU TK, LOWN JW, DICKERSON RE: Defining GC-specificity in the minor groove: side-by-side binding of the diimidazole lexitropsin to C-A-T-G-G-C-C-A-T-G. Structure (1997) 5:1033-1046.
59. CHEN X, RAMAKRISHNAN B, SUNDARALINGAM M: Crystal structures of the side-by-side binding of distamycin to AT-containing DNA octamers d(ICITACIC) and d(ICATATIC). J. Mol. Biol. (1997) 267:1157-1170.
60. KERS I, DERVAN PB: Search for the optimal linker in tandem hairpin polyamides. Bioorg. Med. Chem. (2002) 10:3339-3349.
61. GOPAL YNV, VAN DYKE MW: Combinatorial determination of sequence specificity for nanomolar DNA-binding hairpin polyamides. Biochemistry (2003) 42:6891-6903.
62. WEYERMANN P, DERVAN, PB: Recognition often base pairs of DNA by head-co-head hairpin dimers. J. Am. Chem. Soc. (2002) 124:6872-6878.
63. DICKINSON LA, TRAUGER JW, BAIRD EE, GHAZAL P, DERVAN PB, GOTTESFELD JM: Anti-repression of RNA polymerase II transcription by pyrrole-imidazole polyamides. Biochemistry (1999) 38:10801-10807.
64. BREMER RE, WURTZ NR, SZEWCZYK JW, DERVAN PB: Inhibition of major groove DNA binding bZIP proteins by positive patch polyamides. Bioorg. Med. Chem. (2001) 9:2093-2103.
65. DICKINSON LA, GULIZIA RJ, TRAUGER JW et al.: Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands. Proc. Natl. Acad. Sci. USA (1998) 95:12890-12895.
66. BROGGINI M, COLEY HM, MONGELLI N et al.: DNA sequenceHspecific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. Nucleic Acids Res. (1995) 23:81-87.
67. SMAILL JB, FAN J-Y, PAPA PV, O'CONNOR CJ, DENNY WA: Mono- and difunctional nitrogen mustard analogues of the DNA minor groove binder pibenzimol. Synthesis, cytotoxicity and interaction with DNA. Anticancer Drug Des. (1998) 13:221-242.
68. HURLEY LH, RECK T, THURSTON DE, HERTZBERG RP et al.: Pyrrolo[1,4]benzodiazepine antitumor antibiotics: relationship of DNA alkylation and sequence specificity to the biological activity of natural and synthetic compounds. Chem. Res. Toxicol. (1988) 1:258-268.
69. TOMASZ M, PALOM Y: The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol. Ther. (1997) 76:73-87.
70. TAATJES DJ, FENICK DJ, KOCH TH: Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines. Chem. Res. Toxicol. (1999) 12:588-596.
71. PRASEUTH D, GUIEYSSE AL, HELENE C: Triple helix formation and the antigene strategy for sequenceHspecific control of gene expression. Biochim. Biophys. Acta (1999) 1489:181-206.
72. NIELSEN PH: Peptide nucleic acids: On the road to new gene therapeutic drugs. Pharmacol. Toxicol. (2000) 86:3-7.
73. FARIA M, GIOVANNANGELI C: Triplex-forming molecules: from concepts to applications. J. Gene Med. (2001) 3:299H310.
74. YANG DC, ELLIOTT RL, HEAD JF: Gene targets of antisense therapies in breast cancer. Expert Opin. Ther. Targets (2002) 6:375-385.
75. UHLMANN E: Peptide nucleic acids (PNA) and PNA-DNA chimeras: from high binding affinity towards biological function. Chem. Biol. (1998) 379:1045-1052.
76. VESTER B, WENGEL J: LNA (Locked Nucleic Acid): High-affinity targeting of complementary RNA and DNA. Biochemistry (2004) 43:13233H13241.
77. GUIEYSSE AL, PRASEUTH D, GIOVANNANGELI C, ASSELINE U, HELENE C: Psoralen adducts induced by triplex-forming oligonucleotides are refractory to repair in HeLa cells. J. Mol. Biol. (2000) 296:373-383.
78. GIRAUD-PANIS M-J, LENG M: Transplatin-modified oligonucleotides as modulators of gene expression. Pharmacol. Ther. (2000) 85:175-181.
79. EHLEY JA, MELANDER C, HERMAN D et al.: Promoter scanning for transcription inhibition with DNA-binding polyamides. Mol. Cell. Biol. (2002) 22:1723-1733.
80. ABDELRAHIM M, SMITH III R, BURGHARDT R et al.: Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res. (2004) 64:6740-6749.
81. MANSILLA S, PRIEBE W, PORTUGAL J: Sp1-targeted inhibition of gene transcription by WP631 in transfected lymphocytes. Biochemistry (2004) 43:7584H7592.
82. DREDGE K, DALGLEISH AG, MARRIOTT JB: Recent developments in antiangiogenic therapy. Expert Opin. Biol. Ther. (2002) 2:953-966.
83. STEPHENS TD, BUNDE CJW, FILLMORE BJ: Mechanism of action in thalidomide teratogenesis. Biochem. Pharmacol. (2000) 59:1489-1499.
84. DRUCKER L, UZIEL O, TOHAMI T et al.: Thalidomide down-regulates transcript levels of GC-rich promoter genes in mutlipe myeloma. Mol. Pharmacol. (2003) 64:415-420.
85. KARIN M, CAO Y, GRETEN FR, LI ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer (2002) 2:301-310.
86. BURD JF, WARTELL RM, DODGSON JB, WELLS RD: Transmission of stability (telestability) in deoxyribonucleic acids. Physical and enzymatic studies on the duplex block polymer d(C15A15)-d(T15G15). J. Biol. Chem. (1975) 250:5109-5113.
87. WHITE CM, SATZ AL, BRUICE TC, BEERMAN TA: Inhibition of transcription factor-DNA complexes and gene expression by a microgonotropen. Proc. Natl. Acad. Sci. USA (2001) 98:10590-10595.
88. KLEIN C, VASSILEV LT: Targeting the p53-MDM2 interaction to treat cancer. Br. J. Cancer (2004) 91:1415-1419.
89. DARNELL JE Jr: Transcription factors targets for cancer therapy. Nat. Rev. Cancer (2002) 2:740-749.
90. KANOH J, ISHIKAWA F. Composition and conservation of the telomeric complex. Cell. Mol. Life Sci. (2003) 60:2295-302.
91. REZLER EM, BEARSS DJ, HURLEY LH. Telomeres and telomerases as drug targets. Curr. Opin. Pharmacol. (2002) 2:415-23.
92. HARRISON RJ, CUESTA J, CHESSARI G et al.: Trisubstituted acridine derivatives as potent and selective telomerase inhibitors. J. Med. Chem. (2003) 46:4463-4476.
93. MANO Y, SHIMIZU T, TANUMA S, TAKEDA, K. Synergistic down-regulation of telomerase activity and hTERT mRNA expression by combination of retinoic acid and GM-CSF in human myeloblastic leukemia ML-1 cells. Anti-Cancer Res. (2000) 20:1649-1652.
94. TRIMMER FE, ZAMBLE DB, LIPPARD SJ, ESSIGMANN JM: Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities. Biochemistry (1998) 37:352-362.
95. WETZEL CC, BERBERICH SJ: p53 binds to cisplatin-damaged DNA. Biochim. Biophys. Acta (2001) 1517:392H397.
96. KASPARKOVA J, FOJTA M, FARRELL N, BRABEC V: Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin. Nucleic Acids Res. (2004) 32:5546-5552.
97. TURCHI JJ, LI M, HENKELS KM: Cisplatin-DNA binding specificity of calf high-mobility group 1 protein. Biochemistry (1996) 35:2992-3000.
98. YARNELL AT, OH S, REINBERG D, LIPPARD SJ: Interaction of FACT, SSRP1, and the high mobility group (HMG) domain of SSRP1 with DNA damaged by the anticancer drug cisplatin. J. Biol. Chem. (2001) 276:25736-25741.
99. ZLATANOVA J, YANEVA J, LEUBA SH: Proteins that specifically recognize cisplatinHdamaged DNA: a clue to anticancer activity of cisplatin. FASEB J (1998) 12:791-799.
100. LEE SJ, HURLEY LH: A thymine: thymine mismatch enhances the pluramycin alkylation site downstream of the TBPHTATA box complex. J. Am. Chem. Soc. (1999) 121:8971-8977.
101. ZEWAIL-FOOTE M, HURLEY LH: Differential rates of reversibility of ecteinascidin 743 - DNA covalent adducts from different sequences lead to migration to favored bonding sites. J. Am. Chem. Soc. (2001) 123:6485-6495.
102. MARCO E, GARCIA-NIETO R, MENDIETA J, MANZANARES I, CUEVAS C, GAGO F: A 3Å (ET743)HDNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions. J. Med. Chem. (2002) 45:871-880.
103. WANG YD, DZIEGIELEWSKI J, CHANG AY, DERVAN PB, BEERMAN TA: Cell-free and cellular activities of a DNA sequence selective hairpin polyamide-CBI conjugate. J. Biol. Chem. (2002) 277:42431-42437.
104. BELITSKY JM, LESLIE SJ, ARORA PS, BEERMAN TA, DERVAN PB: Cellular uptake of N-methylpyrrole/ NHmethylimidazole polyamide-dye conjugates. Bioorg. Med. Chem. (2002) 10:3313-3318.
105. BARALDI PG, BOVERO A, FRUTTAROLO F et al.: DNA minor groove binders as potential antitumor and antimicrobial agents. Med. Res. Rev. (2004) 24:475-528.
106. CUTTS SM, PARSONS PG, STURM RA, PHILLIPS DR: Adriamycin-induced DNA adducts inhibit the DNA interactions of transcription factors and RNA Polymerase. J. Biol. Chem. (1996) 271:5422-5429.
107. GRIGORIEV M, PRASEUTH D, ROBIN P et al.: A triple helix-forming oligonucleotide-intercalator conjugate acts as a transcriptional repressor via inhibition of NFκB binding to interleukin-2 receptor α-regulatory sequence. J. Biol. Chem. (1992) 267:3389-3395.
108. CRINELLI R, BIANCHI M, GENTILINI L et al.: Transcription factor decoy oligonucleotides modified with locked nucleic acids: an in vitro study to reconcile biostability with binding affinity. Nucleic Acids Res. (2004) 32:1874H1885.
109. PARK YG, NESTEROVA M, AGRAWAL S, CHO-CHUNG YS: Dual blockade of cyclic AMP response element-(CRE) and AP-1-directed transcription by CRE-transcription factor decoy oligonucleotide, gene-specific inhibition of tumor growth. J. Biol. Chem. (1999) 274:1573-1580.
110. YANG X, FENNEWALD S, LUXON BA, ARONSON J, HERZOG NK, GORENSTEIN DG: Aptamers containing thymidine 3′-O-phosphorodithioates: Synthesis and binding to nuclear factor-κB. Bioorg. Med. Chem. Lett. (1999) 9:3357-3362.
111. MISCHIATI C, BORGATTI M, BIANCHI N et al.: Interaction of the human NF-κB p52 transcription factor with DNA-PNA hybrids mimicking the NF-κB binding sites of the human immunodeficiency virus Type 1 promoter. J. Biol. Chem. (1999) 274:33114-33122.
112. BORGATTI M, LAMPRONTI I, ROMANELLI A et al.: Transcription factor decoy molecules based on a peptide nucleic acid (PNA)-DNA chimera mimicking SP1 binding sites. J. Biol. Chem. (2003) 278:7500-7509.
113. AGRAWAL S, KANDIMALLA ER: Antisense therapeutics: is it as simple as complementary base recognition. Mol. Med. Today (2000) 6:72-81.
114. WAGNER AH, KRZESZ R, GAO D, SCHROEDER CH, CATTARUZZA M, HECKER M: Decoy oligodeoxynucleotide characterization of transcription factors controlling endothelin-B receptor expression in vascular smooth muscle cells. Mol. Pharmacol. (2000) 58:1333-1340.
115. COOPER JAD, PARKS JM, CARCELEN R, KAHLON SS, SHEFFIELD M, CULBRETH R: Attenuation of interleukin-8 production by inhibiting nuclear factor-κB translocation using decoy oligonucleotides. Biochem. Pharmacol. (2000) 59:605-613.
116. LAMBERTINI E, PENOLAZZI L, AGUIARI G et al. Osteoblastic differentiation induced by transcription factor decoy against estrogen receptor α gene. Biochem. Biophys. Res. Comm. (2002) 292:761-770.
117. CHATTERJEE S, ZAMAN K, RYU H, CONFORTO A, RATAN RR: Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann. Neurol. (2001) 49:345-354.
118. RINK SM, YAREMA KJ, SOLOMON MS et al.: Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor. Biochemistry (1996) 93:15063-15068.
119. BECKERBAUER L, TEPE JJ, CULLISON J, REEVES R, WILLIAMS RM: FR900482 class of antiHtumor drugs cross-links oncoprotein HMG I/Y to DNA in vivo. Chem. Biol. (2000) 7:805-812.
120. SAMUEL SK, SPENCER VA, BAJNO L et al.: in situ cross-linking by cisplatin of nuclear matrix-bound transcription factors to nuclear DNA of human breast cancer cells. Cancer Res. (1998) 58:3004-3008.
121. PALANKI MSS: Inhibitors of AP-1 and NF-κB mediated transcriptional activation: Therapeutic potential in autoimmune diseases and structural diversity. Curr. Med. Chem. (2002) 9:219-227.
122. IJAZ T, TRAN P, RUPARELIA KC, TEESDALE-SPITTLE PH, ORR S, PATTERSON LH: Anthraquinone-peptides as inhibitors of AP-1 transcription factor. Bioorg. Med. Chem. Lett. (2001) 11:351-353.
123. ZHANG Z, CHALTIN P, VAN AERSCHOT A et al.: New dsDNA binding unnatural oligopeptides with pyrimidine selectivity. Bioorg. Med. Chem. (2002) 10:3401-3413.